BR112016030577A8 - polipeptídeos multiméricos do domínio de haste da hemaglutinina da gripe, molécula de ácido nucleico, vetor, composição e usos destes - Google Patents

polipeptídeos multiméricos do domínio de haste da hemaglutinina da gripe, molécula de ácido nucleico, vetor, composição e usos destes

Info

Publication number
BR112016030577A8
BR112016030577A8 BR112016030577A BR112016030577A BR112016030577A8 BR 112016030577 A8 BR112016030577 A8 BR 112016030577A8 BR 112016030577 A BR112016030577 A BR 112016030577A BR 112016030577 A BR112016030577 A BR 112016030577A BR 112016030577 A8 BR112016030577 A8 BR 112016030577A8
Authority
BR
Brazil
Prior art keywords
multimeric
stem domain
vector
nucleic acid
composition
Prior art date
Application number
BR112016030577A
Other languages
English (en)
Other versions
BR112016030577A2 (pt
Inventor
Impagliazzo Antonietta
Wilem Meijberg Jan
Radosevic Katarina
Wagner Michelle
Ding Zhaoqing
Original Assignee
Janssen Vaccines & Prevention Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55063616&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112016030577(A8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Vaccines & Prevention Bv filed Critical Janssen Vaccines & Prevention Bv
Publication of BR112016030577A2 publication Critical patent/BR112016030577A2/pt
Publication of BR112016030577A8 publication Critical patent/BR112016030577A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/11—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

polipeptídeos multiméricos do do- mínio de haste da hemaglutinina da gripe, molécula de ácido nucleico, vetor, composição e usos destes. são fornecidos aqui polipeptídeos multiméricos do domínio de haste da hemaglutinina da gripe, métodos para proporcionar poli-peptídeos do domínio de haste da hemaglutinina, composições compreendendo os mesmos, vacinas compreendendo os mesmos e métodos de seu uso, em particular na detecção, prevenção e/ou tratamento da gripe.
BR112016030577A 2014-07-10 2015-07-09 polipeptídeos multiméricos do domínio de haste da hemaglutinina da gripe, molécula de ácido nucleico, vetor, composição e usos destes BR112016030577A8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP14176459 2014-07-10
US201462062754P 2014-10-10 2014-10-10
EP14195143 2014-11-27
EP15155761 2015-02-19
PCT/EP2015/065663 WO2016005482A1 (en) 2014-07-10 2015-07-09 Influenza virus vaccines and uses thereof

Publications (2)

Publication Number Publication Date
BR112016030577A2 BR112016030577A2 (pt) 2017-10-31
BR112016030577A8 true BR112016030577A8 (pt) 2021-07-20

Family

ID=55063616

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016030577A BR112016030577A8 (pt) 2014-07-10 2015-07-09 polipeptídeos multiméricos do domínio de haste da hemaglutinina da gripe, molécula de ácido nucleico, vetor, composição e usos destes

Country Status (17)

Country Link
US (1) US10117925B2 (pt)
EP (1) EP3166963B1 (pt)
JP (1) JP7094103B2 (pt)
KR (1) KR102463632B1 (pt)
CN (1) CN107074912B (pt)
AU (1) AU2015286723B2 (pt)
BR (1) BR112016030577A8 (pt)
CA (1) CA2953451C (pt)
CL (1) CL2017000064A1 (pt)
EA (1) EA035375B1 (pt)
MX (1) MX2017000395A (pt)
MY (1) MY182440A (pt)
PE (1) PE20170291A1 (pt)
PH (1) PH12016502468B1 (pt)
SG (1) SG11201610456UA (pt)
WO (1) WO2016005482A1 (pt)
ZA (1) ZA201700165B (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010117786A1 (en) 2009-03-30 2010-10-14 Mount Sinai School Of Medicine Of New York University Influenza virus vaccines and uses thereof
CA2857087C (en) 2011-11-28 2021-05-25 Crucell Holland B.V. Influenza virus vaccines and uses thereof
JP2016508133A (ja) 2012-12-18 2016-03-17 アイカーン スクール オブ メディシン アット マウント サイナイ インフルエンザウイルスワクチン及びその使用
WO2014159960A1 (en) 2013-03-14 2014-10-02 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
WO2014191435A1 (en) 2013-05-30 2014-12-04 Crucell Holland B.V. Influenza virus vaccines and uses thereof
AU2015286721B2 (en) 2014-07-10 2019-11-21 Janssen Vaccines & Prevention B.V. Influenza virus vaccines and uses thereof
JP2018504412A (ja) 2015-01-23 2018-02-15 アイカーン スクール オブ メディシン アット マウント サイナイ インフルエンザウイルスワクチン接種レジメン
CA3023143A1 (en) 2016-06-15 2017-12-21 Icahn School Of Medicine At Mount Sinai Influenza virus hemagglutinin proteins and uses thereof
EP3506938A1 (en) 2016-09-02 2019-07-10 The U.S.A. as represented by the Secretary, Department of Health and Human Services Stabilized group 2 influenza hemagglutinin stem region trimers and uses thereof
WO2018187706A2 (en) 2017-04-07 2018-10-11 Icahn School Of Medicine At Mount Sinai Anti-influenza b virus neuraminidase antibodies and uses thereof
CN107765001B (zh) * 2017-10-24 2020-03-27 中国科学院苏州纳米技术与纳米仿生研究所 禽流感病毒感染或禽流感疫苗免疫分型试剂盒
SG11202006399VA (en) 2018-01-23 2020-08-28 Janssen Vaccines & Prevention Bv Influenza virus vaccines and uses thereof
US11576964B2 (en) * 2018-03-28 2023-02-14 Sanofi Pasteur Inc. Methods of generating broadly protective vaccine compositions comprising hemagglutinin
CN109239355B (zh) * 2018-09-05 2020-08-25 中牧实业股份有限公司 禽流感病毒h9亚型抗体酶联免疫检测试剂盒
BR112021005255A2 (pt) * 2018-09-21 2021-06-29 Board Of Regents Of The University Of Nebraska método de produção e uso de genes para vacina contra a influenza centralizada universal
CA3152957A1 (en) * 2019-09-05 2021-03-11 Janssen Vaccines & Prevention B.V. Influenza virus vaccines and uses thereof
GB202004825D0 (en) * 2020-04-01 2020-05-13 Diosynvax Ltd Influenza vaccines
BR112023004123A2 (pt) * 2020-09-07 2023-04-04 Intervet Int Bv Vacina de haste da ha para alvos positivos de anticorpos de ha
TW202317600A (zh) * 2021-06-23 2023-05-01 潤惠生技股份有限公司 預防多種病毒感染的多價疫苗
WO2023154821A2 (en) * 2022-02-11 2023-08-17 University Of Washington Compositions comprising influenza hemagglutinin stem and method for enhancing cross-protective immunity
WO2023198815A1 (en) 2022-04-14 2023-10-19 Janssen Vaccines & Prevention B.V. Sequential administration of adenoviruses
CN116589566A (zh) * 2022-11-18 2023-08-15 昆明医科大学第一附属医院 一种HIV-1中和抗体的改造重组单克隆IgM抗体及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA017203B1 (ru) 2006-09-07 2012-10-30 Круселл Холланд Б.В. Связывающие молекулы человека, способные нейтрализовать вирус гриппа h5n1, и их применение
WO2010117786A1 (en) * 2009-03-30 2010-10-14 Mount Sinai School Of Medicine Of New York University Influenza virus vaccines and uses thereof
NZ596032A (en) 2009-05-11 2013-09-27 Crucell Holland Bv Human binding molecules capable of neutralizing influenza virus h3n2 and uses thereof
AU2011235220B2 (en) * 2010-03-30 2016-03-10 Mount Sinai School Of Medicine Influenza virus vaccines and uses thereof
US8900585B2 (en) * 2010-10-20 2014-12-02 New York Blood Center, Inc. Influenza hemagglutinin-specific monoclonal antibodies for preventing and treating influenza virus infection
WO2013007770A1 (en) 2011-07-14 2013-01-17 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza a viruses of phylogenetic group 1 and phylogenetic group 2 and influenza b viruses
CA2857087C (en) * 2011-11-28 2021-05-25 Crucell Holland B.V. Influenza virus vaccines and uses thereof
WO2014191435A1 (en) * 2013-05-30 2014-12-04 Crucell Holland B.V. Influenza virus vaccines and uses thereof
AU2015286721B2 (en) 2014-07-10 2019-11-21 Janssen Vaccines & Prevention B.V. Influenza virus vaccines and uses thereof

Also Published As

Publication number Publication date
JP2017521073A (ja) 2017-08-03
CA2953451C (en) 2023-09-19
US20170189519A1 (en) 2017-07-06
BR112016030577A2 (pt) 2017-10-31
EP3166963A1 (en) 2017-05-17
MY182440A (en) 2021-01-25
US10117925B2 (en) 2018-11-06
ZA201700165B (en) 2019-06-26
WO2016005482A1 (en) 2016-01-14
CA2953451A1 (en) 2016-01-14
KR102463632B1 (ko) 2022-11-03
EA035375B1 (ru) 2020-06-03
EP3166963B1 (en) 2020-04-22
PH12016502468A1 (en) 2017-04-10
CL2017000064A1 (es) 2017-11-10
PH12016502468B1 (en) 2017-04-10
KR20170027846A (ko) 2017-03-10
JP7094103B2 (ja) 2022-07-01
SG11201610456UA (en) 2017-01-27
AU2015286723B2 (en) 2019-11-21
CN107074912A (zh) 2017-08-18
AU2015286723A1 (en) 2017-01-12
CN107074912B (zh) 2021-10-29
PE20170291A1 (es) 2017-03-26
MX2017000395A (es) 2018-02-08
EA201692467A1 (ru) 2017-05-31

Similar Documents

Publication Publication Date Title
BR112016030577A8 (pt) polipeptídeos multiméricos do domínio de haste da hemaglutinina da gripe, molécula de ácido nucleico, vetor, composição e usos destes
BR112017000257A2 (pt) vacinas contra o vírus da gripe e usos das mesmas
EA201792500A1 (ru) Aav-опосредованная экспрессия антител против гриппа и способы их использования
BR112015014482A2 (pt) vacinas para vírus influenza e seus usos
CY1120937T1 (el) Φαρμακευτικη μορφοποιηση αντισωματος anti-tnf-αλφα
DK3674298T3 (da) Substituerede indazoler, fremgangsmåde til deres fremstilling, farmaceutiske præparater, der indeholder disse, samt deres anvendelse til fremstilling af lægemidler
BR112016022814A8 (pt) composição farmacêutica e seu método de preparação, ácido nucleico, e dispositivo médico ou kit médico
DK3559022T3 (da) Virulenssvækket bakteriebaseret proteinlevering
BR112016030787A2 (pt) entidade química, composição farmacêutica e seu uso
BR112017016902A2 (pt) composição farmacêutica, respectivo uso e método para tratar câncer
BR112015031509A2 (pt) Polipeptídeo, molécula de ácido nucleico, vetor, e, composição
BR112016026556A2 (pt) inibidores de mek, de p38 e/ou de nfkb, seus usos, composição, sistema de teste in vitro, seu uso, e método para detecção de moléculas eficazes na profilaxia e/ou tratamento de uma co-infecção
BR112016022062A2 (pt) Combinação, composição farmacêutica, uso de uma combinação ou de uma composição farmacêutica, e, produto farmacêutico
BR112015030582A2 (pt) Segmento de hemaglutinina da gripe quimérico e de neuraminidase quimérico, proteína de hemaglutinina quimérica, vírus da gripe rearranjado, métodos para preparação de um vírus da gripe rearranjado e para preparação de uma vacina e sistema de expressão
BR112015025748A2 (pt) construção de dna para imunomodulação, composição farmacêutica, vacina, e uso de uma construção de dna
CL2019001493A1 (es) Exopolisacáridos y usos de los mismos.
BR112017009792A2 (pt) anticorpos anti-pdgf-b e métodos de uso
BR112016026552A2 (pt) derivados de carboxamida, seus usos, composição farmacêutica, e combinação
BR112016019868A2 (pt) proteínas de fusão tatk-cdkl5, composições, formulações, e seu uso
BR112016023833A2 (pt) compostos, composições, métodos e uso para tratar ou prevenir infecções por vírus da hepatite c
CL2020001901A1 (es) Vacunas contra virus de la gripe y usos de las mismas.
WO2014152946A3 (en) Polypeptides for treating and/or limiting influenza infection
BR112016027383A2 (pt) Derivados de naftiridinadiona, seus usos, composição farmacêutica e combinação
DK3455216T3 (da) Pyridinylderivater, farmaceutiske sammensætninger og anvendelser deraf som aoc3-inhibitorer
BR112017004552A2 (pt) composições farmacêuticas

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]